High Pressure, Low Control: The Challenging Side Of Resistant Arterial Hypertension

Authors

  • Mariana Caetano Coelho Interna de Formação Especifica em Cardiologia – Centro Hospitalar Barreiro-Montijo
  • Adriana Silva Interna de Formação Especifica em Cardiologia – Centro Hospitalar Barreiro-Montijo
  • Margarida Figueiredo Interna de Formação Especifica em Cardiologia – Centro Hospitalar Barreiro-Montijo
  • Sofia Paula Interna de Formação Especifica em Cardiologia – Centro Hospitalar Barreiro-Montijo

DOI:

https://doi.org/10.58043/rphrc.155

Keywords:

Resistant Arterial Hypertension, Pharmacological Resistance, Treatment, New Therapeutic Alternatives

Abstract

Arterial hypertension constitutes a highly prevalent cardiovascular risk factor in the global population. However, a significant portion of patients fails to achieve adequate blood pressure levels for effective risk control, challenging medical practice. Resistant hypertension is identified when the patient maintains blood pressure levels above the recommended value, even with the concurrent use of three anti-hypertensive medications at optimized doses, one of which is a diuretic. This clinical case illustrates a case of resistant arterial hypertension and the various therapeutic approaches used in blood pressure control.

Downloads

Download data is not yet available.

References

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guidelines for the management of high blood pressure in adults; Report from the panel members appointed to the eighth joint national committee ( JNC 8). JAMA 2014;311:507-20.

Pimenta E, Calhoun D. Treatment of resistant hypertension. J Hypertension 2010;28:2194-5.

Michel Azizi, MD; Manish Saxena, MBBS, MSc; Yale Wang, MD; et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension. The RADIANCE II Randomized Clinical Trial. AMA. 2023;329(8):651-661.

Prof Felix Mahfoud, MD; David E Kandzari, MD; Prof Kazuomi Kario, MD; Prof Raymond R Townsend, MD; Prof Michael A Weber, MD; Prof Roland E Schmieder, MD; et al. L ong-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022; 399:1401-1410.

Bhatt D, Kandzari D, O’Neil W, D’Agostino R, Flack J, Katzen B, et al. A controlled trial of renal denervation for Journal of Family Medicine and Primary Care resistant hypertension. N Engl J Med 2014;370:1393-401.

Bisognano J, Bakris G, Nadim M, Sanchez L, Kroon A, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension; results from the double blind, randomised, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol 2011;58:765-73.

Luke J. Laffin, MD1,2; David Rodman, MD3; James M. Luther, MD4; et al. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension. The Target-HTN Randomized Clinical Trial. JAMA. 2023;330(12):1140-1150.

Akshay S. Desai, M.D., M.P.H., David J. Webb, M.D., D.Sc., Jorg Taubel, M.D., Sarah Casey, M.B., Ch.B., Yansong Cheng, Ph.D., Gabriel J. Robbie, Ph.D., Don Foster, M.S., Stephen A. Huang, M.D., Sean Rhyee, M.D., M.P.H., Marianne T. Sweetser, M.D., Ph.D., and George L. Bakris, M.D. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med 2023; 389:228-238.

Downloads

Published

2025-01-27

How to Cite

1.
Caetano Coelho M, Silva A, Figueiredo M, Paula S. High Pressure, Low Control: The Challenging Side Of Resistant Arterial Hypertension. RH [Internet]. 2025 Jan. 27 [cited 2025 Feb. 22];(105):30-3. Available from: https://revistahipertensao.pt/index.php/rh/article/view/155

Issue

No. 105 (2025): January - March

Section

Caso Clínico

License

Copyright (c) 2025 Mariana Caetano Coelho

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.